Investigational Drug Information for Ruboxistaurin
✉ Email this page to a colleague
What is the drug development status for Ruboxistaurin?
Ruboxistaurin is an investigational drug.
There have been 14 clinical trials for Ruboxistaurin.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2002.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetic Neuropathies, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Chromaderm, Inc., Eli Lilly and Company, and The Christ Hospital.
Summary for Ruboxistaurin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 540 |
| WIPO Patent Applications | 349 |
| Japanese Patent Applications | 205 |
| Clinical Trial Progress | Phase 3 (2002-07-01) |
| Vendors | 32 |
Recent Clinical Trials for Ruboxistaurin
| Title | Sponsor | Phase |
|---|---|---|
| Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos | DermBiont, Inc. | Phase 2 |
| Ruboxistaurin in New York Heart Failure Classification III-IV Patients | The Christ Hospital | Phase 1/Phase 2 |
| Ruboxistaurin in New York Heart Failure Classification III-IV Patients | Children's Hospital Medical Center, Cincinnati | Phase 1/Phase 2 |
Clinical Trial Summary for Ruboxistaurin
Top disease conditions for Ruboxistaurin
Top clinical trial sponsors for Ruboxistaurin
US Patents for Ruboxistaurin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
